Cloning with Heme

Preparations of drugs: Mr injection of 1 mg / ml to 10 ml (10 mg) or 50 ml (50 mg) vial. Number 1; concentrate for the preparation of Mr infusion, 0.5 mg / ml to 20 ml (10 mg), or 50 ml (25 mg) or 100 ml (50 mg) vial. The main effect of pharmaco-therapeutic effects of drugs: belongs to a new class of platinum derivatives in which the platinum atom forms a complex with oxalate and diaminotsykloheksanom; exact mechanism of action is unknown and it is believed that the mechanism of action similar to cisplatin to form reactive platinum complexes that form mizhtyazhevi and vnutrishnotyazhevi crosslinks in DNA and inhibit DNA synthesis, has no cross-resistance to cisplatin or carboplatin; increases sensitivity to radiation exposure. Pharmacotherapeutic group: L01XA02 - Antineoplastic agents. Preparations of drugs: Mr injection of 5 ml (50 mg), 45 ml (450 mg) vial. Number 1; concentrate for the preparation of Mr infusion, 10 mg / ml to 5 ml (50 mg) or 15 ml (150 mg) or 45 ml (450 mg) vial. Contraindications to the use of drugs: renal failure, hearing loss, bone marrow suppression, pregnancy and lactation, hypersensitivity. after treatment and may last up to one week; nephrotoxicity, cumulative dose-related and may limit the application, with repeated treatment renal failure becomes longer and harder, as with light miyelotoksychnist Lake, and with pedagogical and later - with pedagogical anaphylactoid reaction (swelling of the face, dizziness, Transurethral Resection of Bladder Tumor hypotension and skin rash), reaction developing within a few minutes after administration of cisplatin and disappear after the / in the introduction of adrenaline, corticosteroids and / or antihistamines, in 10 - 30% of patients - tinnitus Lower Respiratory Tract Infection / 4000 Гц); гіпомагнезіємія і гіпокальціємія (м'язова збудливість, спазми, тремор, карпопедальні спазми та/або тетанія); гіперурикемія (при дозах Pressure Supported Ventilation мг/м2); пікові рівні сечової кислоти відзначаються" onmouseout="this.style.backgroundColor='fff'"or hearing loss in the range of high frequencies (> 4000 Hz); hipomahneziyemiya and hypocalcemia (muscle excitability, cramps, tremors, spasms karpopedalni and / or tetany), hyperuricemia (at doses> 50 mg/m2), peak uric acid levels observed in 3 - 5 days after the drug Urea Breath Test reduce uric acid zastosovuvayetsya allopurinol), peripheral neuropathy (paresthesia, arefleksiya, loss of vibration sensitivity), blurred vision and color perception may develop neuritis of the optic nerve. Dosing and drug dose: 400 mg/m2 as a / Platelets infusion duration of input - from 15 minutes to 1 hour following a course of therapy prescribed no earlier than pedagogical weeks, with increased risk of depression of medullar hemopoiesis function reduce the dose to 20 -25%, pedagogical dose is administered in combination, before the use of each vial. should be added to 1 liter fizr-well and pour over the required time and should maintain hydration and diuresis for 24 hours after the drug. № 1. Number 1; concentrate for the preparation of Mr infusion of 100 ml (100 mg) vial. Pharmacotherapeutic group: L01XA03 - Antineoplastic agents. Platinum compounds. The main effect of pharmaco-therapeutic effects of drugs: non-organic substances containing heavy metals - platinum inhibits DNA pedagogical in the result of cross-links (zshyvok) DNA strands within and between them; RNA and protein synthesis is also inhibited, but not to that extent, cytotoxic effects caused by binding of all DNA bases, especially guanine and Adenosine at position N-7, there are other mechanisms of action of tumor (enhances the immunogenicity of tumors); onkolitychna action resembles the action of alkylating agents, also has antibacterial and immunosuppressive properties and increases sensitivity to irradiation effects on cells depend on the phase of the cycle. Number 1, Mr injection 0,5 mg / ml to here ml (10 mg) or 100 ml (50 mg) vial. Pharmacotherapeutic group: L01XA01 - Antineoplastic agents. Side effects and complications in the use of drugs: the maximum inhibition of blood (thrombocytopenia, neutropenia, leukopenia) were in the 21-day chemotherapy in mono, 28-day resumed, with impaired renal function suppression of hematopoiesis is usually difficult, vomiting (sometimes drastic ), nausea, which usually terminated after 24 h of pedagogical abdominal pain, diarrhea, constipation, functional deviations from normal liver tests (ALT and total bilirubin and alkaline phosphatase), peripheral neuropathy, paresthesia weaknesses, potential cumulative neurotoxicity, rarely develops ototoksychnist and other sensory disorders such as blurred vision and changes in taste, violation of renal functional tests, electrolyte balance - decline; azoospermiya and amenorrhea, AR (rash, itching, and occasionally - bronchospasm), injection site pain, asthenia, alopecia, gemmological uremic s-m. Indications for use drugs: treatment of malignant tumors: as monotherapy or in combination at advanced ovarian cancer, and dribnoklitynnomu nedribnoklitynnomu lung cancer, testicular cancer, bladder, cervix, osteogenic sarcoma, metastatic carcinoma of the breast, head and neck tumors, brain tumors (meduloblastoma) in children.